

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	SIGMA PHARMACEUTICALS LIMITED
ABN	15 088 417 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mark Robert Hooper
Date of last notice	2/11/2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	Tranche 1 - 16/01/2017, Tranche 2 - 17/01/2017, Tranche 3 - 19/01/2017 Tranche 4 - 23/01/2017
No. of securities held prior to change	34,543,184 Ordinary Shares 5,812,335 Shares allocated pursuant to the employee share plan 33,612 Shares allocated pursuant to the loan funded long term incentive plan 28,459,560 Short term incentive plan performance rights 237,677

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Class	Ordinary
Number acquired	N/A
Number disposed	885,796
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$1,099,998.99
No. of securities held after change	33,657,388 Ordinary Shares 4,926,539 Shares allocated pursuant to the employee share plan 33,612 Shares allocated pursuant to the loan funded long term incentive plan 28,459,560 Short term incentive plan performance rights 237,677
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	885,796 ordinary shares sold on market in 4 tranches 16/01/2017 – 260,508 ordinary shares 17/01/2017 – 200,000 ordinary shares 19/01/2017 – 201,059 ordinary shares 23/01/2017 – 224,229 ordinary shares

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.